BioArctic AB
BIOA-B.STDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Jul 15, 2026
12dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
Conference — Leqembi
For Alzheimer's disease. Eisai will present new clinical and real-world evidence on lecanemab (Leqembi) at the Alzheimer's Association International Conference in London, July 12-15, 2026. BioArctic AB is partnered with Eisai on this program.
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
exidavnemab | Phase 2 | Parkinson Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BioArctic AB's drug pipeline?→
CatalystAlert tracks 1 drug candidate in BioArctic AB's (BIOA-B.ST) pipeline across Phase 2. Its lead program is exidavnemab (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BioArctic AB's next FDA catalyst?→
BioArctic AB's (BIOA-B.ST) next tracked catalyst is a Conference expected July 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BIOA-B.ST biotech catalysts?→
Add BIOA-B.ST to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioArctic AB's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.